International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 08 August 2023

Page No: 1481-1485

DOI: https://doi.org/10.47191/ijmscrs/v3-i8-01, Impact Factor: 6.597

Heavy Use of Diuretics vs. Ultrafiltration in Cardiorenal Overload Syndrome: A Literature Review

Karen Alejandra Zebadúa Ramírez[1], Jorge Arturo Diaz Cancino[2], Cristian Josué Sosa Álvarez[3]

[1]Departamento de medicina interna, Instituto Mexicano del Seguro Social, Mérida, Yucatán, Mexico

[2,3]Departamento de medicina interna, Instituto Mexicano del Seguro Social, Jesús María, Aguascalientes, Mexico

ABSTRACT

The Cardiorenal Syndrome (CRS) is a complex clinical entity that involves a bidirectional interaction between the heart and kidneys, with a high incidence among patients with cardiovascular and renal diseases. Volume overload is a central feature of CRS, and its optimal management poses a challenge for healthcare professionals. In this context, both the intensive use of diuretics and ultrafiltration have gained prominence as therapeutic strategies to address volume overload and alleviate systemic congestion in patients with CRS.

Objective: This review aims to critically compare the efficacy, safety, and practical considerations of the intensive use of diuretics versus ultrafiltration in the management of volume overload in CRS.

Methods: A comprehensive review of the literature was conducted, encompassing studies, clinical trials, and meta-analyses comparing the two therapeutic approaches in CRS.

Results: The intensive use of diuretics, particularly loop diuretics, has been widely employed due to its rapid action and availability in various clinical settings. Diuretics effectively increase sodium and water excretion, resulting in reduced circulating volume and relief of pulmonary and peripheral congestion. On the other hand, ultrafiltration offers a more precise and controlled elimination of fluids, potentially benefitting patients sensitive to fluid and electrolyte imbalances. Ultrafiltration may be a viable option in patients with diuretic resistance or those at risk of electrolyte depletion. However, current evidence is limited and inconclusive regarding the superiority of one strategy over the other in terms of efficacy.

Conclusion: The choice between the intensive use of diuretics and ultrafiltration should be based on individualized patient assessment, considering the severity of volume overload, renal function, diuretic tolerance, and comorbidities. Both therapeutic approaches have advantages and drawbacks, and a one-size-fits-all approach is not suitable for CRS management. Further large-scale, well-designed clinical trials are required to establish the optimal therapeutic approach in CRS. Multidisciplinary collaboration and personalized treatment based on evidence and clinical experience are crucial for optimizing clinical outcomes and improving the quality of life of patients with CRS and volume overload.

ARTICLE DETAILS

Published On:
01 August 2023

Available on:
https://ijmscr.org/

INTRODUCTION

Cardiorenal syndrome (CRS) is a complex and challenging clinical entity characterized by a bidirectional interaction between the heart and kidneys, where dysfunction of one of these organs negatively affects the other. RCS has acquired significant importance in medical practice due to its high prevalence, its pathophysiological complexity and its unfavorable prognostic impact on patients' health.

The epidemiology of RCS is closely linked to the increasing incidence of cardiovascular and renal diseases worldwide. It is estimated that millions of people suffer from chronic heart and kidney disease, and many of these patients are at risk of developing SCR. Chronic heart failure, ischemic heart disease, high blood pressure and chronic kidney disease are some of the main factors that predispose to the development of SCR.

In the clinical context, RCS is classified into five subtypes, ranging from acute or chronic heart dysfunction that induces corresponding renal dysfunction, to renal dysfunction that contributes to impaired cardiac function. This classification provides a basis for understanding the different pathophysiological interactions and helps in the identification and proper management of each type of SCR.

RCS presents a spectrum of clinical manifestations ranging from fluid retention and systemic congestion to decompensated heart failure and acute renal dysfunction. Patients affected by SCR experience a considerable burden of symptoms and complications, resulting in a significant reduction in quality of life and an increase in short- and long-term morbidity and mortality.

In this context, optimal management of CRS has become a critical goal for healthcare professionals. Different therapeutic strategies have been developed to address this complex condition, with the aim of improving clinical outcomes and quality of life for patients.

Among the major therapeutic strategies used to address SCR, intensive diuretic use and ultrafiltration have gained prominence in managing volume overload and congestion. Diuretics, such as carbonic anhydrase inhibitors, loop diuretics, and thiazides, are widely used to increase sodium and water excretion and relieve fluid retention. On the other hand, ultrafiltration, an extracorporeal fluid removal technique, has emerged as an alternative to the intensive use of diuretics, providing a more precise and controlled approach to fluid removal and avoiding excessive electrolyte depletion.

The objective of this literature review article is to critically examine and compare the intensive use of diuretics and ultrafiltration as therapeutic strategies for the management of volume overload in patients with SCR. The mechanisms of action, indications, advantages and disadvantages, as well as complications associated with each approach will be explored. In addition, the current scientific evidence on the efficacy and safety of both therapeutic strategies will be analyzed to provide a comprehensive and evidence-based vision for clinical decision-making in the management of SCR.

In-depth knowledge of the clinical and pathophysiological characteristics of RCS, as well as the therapeutic options available, is essential to optimize the care of patients affected by this complex entity. Through this literature review, it is hoped to contribute to current scientific knowledge and promote more informed and evidence-based care to improve clinical outcomes and quality of life for patients with RCS.

DEFINITION OF CARDIORENAL SYNDROME

Cardiorenal syndrome (CRS) is a complex interaction between the heart and kidneys, where dysfunction of one of these organs leads to dysfunction of the other, creating a vicious cycle that perpetuates the patient's clinical deterioration. RCS is characterized by a variety of pathologies involving both the heart and kidneys, and has been classified into five subtypes according to cause and predominant mechanism.

SCR Type 1: It is the acute dysfunction of the heart that leads to acute dysfunction of the kidney. This occurs against the background of acute cardiovascular events, such as acute coronary syndrome, decompensated heart failure or ventricular arrhythmia, which trigger a rapid decrease in renal perfusion and the onset of acute renal dysfunction.

SCR Type 2: It is the chronic dysfunction of the heart that induces chronic renal dysfunction. In this situation, chronic heart failure or chronic heart disease, such as dilated cardiomyopathy, results in a progressive decrease in renal blood flow and chronic kidney injury.

SCR Type 3: It is the acute dysfunction of the kidney that contributes to the acute dysfunction of the heart. In this case, an event that causes acute renal dysfunction, such as acute tubular necrosis due to sepsis or exposure to nephrotoxicants, can trigger rapid fluid and sodium retention, leading to volume overload and cardiac decompensation.

SCR Type 4: It is the chronic dysfunction of the kidney that contributes to chronic dysfunction of the heart. A progressive chronic kidney disease, such as chronic glomerulonephritis or diabetic nephropathy, can lead to chronic fluid and sodium retention, leading to sustained volume overload and chronic cardiac dysfunction.

SCR Type 5: Represents a situation in which the patient presents with both heart failure and chronic kidney disease without a clear causal link between the two, but where both conditions aggravate each other.

PATHOPHYSIOLOGY

The pathophysiology of RCS is multifactorial and complex, involving a number of interrelated mechanisms that lead to cardiorenal dysfunction. Decreased cardiac output and reduced renal blood flow play a crucial role in the pathophysiology of SCR, as they lead to a reduction in renal perfusion and activation of the renin-angiotensin-aldosterone system and the sympathetic nervous system.

The activation of the renin-angiotensin-aldosterone system causes the retention of sodium and water, generating a volume overload that affects both the heart and the kidneys. This in turn can lead to increased systemic congestion, decreased cardiac output, and compromised kidney function.

Inflammation also plays a significant role in the pathophysiology of SCR. The release of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha), contributes to endothelial damage, vascular dysfunction, and activation of proinflammatory responses in both organs, exacerbating cardiorenal dysfunction.

Heavy Use of Diuretics

Intensive use of diuretics is a commonly employed strategy in the management of SCR to address volume overload and relieve systemic congestion. Diuretics act on different segments of the nephron to increase sodium and water excretion, thereby reducing volume overload.

Loop diuretics, such as furosemide and torsemide, are widely used in the context of SCR due to their rapid action and potent diuretic effect. These agents inhibit sodium reabsorption in the loop of Henle, which increases the excretion of sodium and water in the urine and reduces circulating volume.

Loop diuretics may also have vasodilatory effects, contributing to the reduction of cardiac preload and relief of pulmonary congestion. In addition, it has been observed that diuretics may improve renal function in the setting of type 1 SCR, by increasing renal perfusion and reducing intra-abdominal pressure in patients with heart failure and ascites.

However, heavy use of diuretics can lead to significant side effects, including depletion of electrolytes such as potassium, magnesium, and calcium, which can lead to cardiac arrhythmias, muscle weakness, and other metabolic disorders. Resistance to diuretics can also develop over time, which can limit their long-term effectiveness in managing volume overload.

Ultrafiltration

Ultrafiltration has emerged as an alternative to the intensive use of diuretics in the management of volume overload and congestion in patients with SCR. Ultrafiltration is an extracorporeal technique that involves the selective removal of water and solutes from the blood, allowing more precise control of fluid removal without excessive electrolyte depletion.

Ultrafiltration is performed through a central venous catheter and an ultrafiltration machine that removes excess fluid from the blood, transferring it to a drainage bag. This technique allows for individualized adjustment of ultrafiltration rate and fluid replacement, which may be beneficial in SCR patients who are sensitive to changes in fluid and electrolyte balance.

Unlike diuretics, ultrafiltration is not subject to renal resistance and does not require adequate renal blood flow for its effectiveness, making it a potentially useful therapeutic option in situations where diuretics have proven ineffective.

In addition, ultrafiltration has been shown to have a beneficial impact on renal function in patients with type 1 SCR, by improving renal perfusion and reducing systemic congestion and intra-abdominal pressure. A lower incidence of electrolyte depletion and better tolerability compared to heavy diuretic use has also been observed.

Advantages

Both intensive use of diuretics and ultrafiltration offer advantages and disadvantages in managing volume overload in the SCR.

The advantages of intensive use of diuretics include their rapid and effective action in reducing circulating volume and improving dyspnea and congestion in patients with decompensated heart failure. In addition, diuretics are widely available and inexpensive, making them an affordable therapeutic option in different clinical settings.

On the other hand, ultrafiltration offers more precise and controlled fluid removal, which may be beneficial in SCR patients who are sensitive to changes in fluid and electrolyte balance. In addition, ultrafiltration prevents excessive electrolyte depletion, which can be a significant advantage compared to diuretics, especially in patients at risk of arrhythmias and other metabolic disorders.

Complications

Both heavy use of diuretics and ultrafiltration are associated with certain complications that should be considered in the management of SCR.

Heavy use of diuretics can lead to depletion of electrolytes, especially potassium and magnesium, which can lead to cardiac arrhythmias and muscle weakness. In addition, resistance to diuretics can develop over time, limiting their long-term effectiveness in managing volume overload.

In the case of ultrafiltration, complications related to vascular access, such as infections of the catheter insertion site and venous thrombosis, have been reported. There is also the risk of fluid and electrolyte imbalances, especially if the ultrafiltration rate and fluid replenishment are not properly adjusted.

DISCUSSION

Cardiorenal syndrome (CRS) is a complex clinical entity that represents a bidirectional interaction between the heart and kidneys, with a high incidence in the population of patients with cardiovascular and renal diseases. Volume overload is a central feature of SCR and its optimal management is a challenge for healthcare professionals. In this context, both intensive diuretic use and ultrafiltration have gained prominence as therapeutic strategies to address volume overload and alleviate systemic congestion in patients with SCR.

Efficiency in Handling Volume Overload

The intensive use of diuretics has been widely used for the management of volume overload in SCR due to their rapid action and availability in different clinical settings. Loop diuretics, such as furosemide and torsemide, are particularly effective in increasing sodium and water excretion, which rapidly reduces circulating volume and relieves pulmonary and peripheral congestion. Diuretics have also been shown to be beneficial in controlling dyspnea and improving cardiac function in the context of decompensated heart failure.

On the other hand, ultrafiltration provides more precise and controlled fluid removal, which may be beneficial in SCR patients who are sensitive to changes in fluid and electrolyte balance. Ultrafiltration may be an effective therapeutic option in situations where diuretics have been shown to be ineffective or in patients with diuretic resistance. In addition, ultrafiltration has been shown to be useful in improving renal function in the context of type 1 SCR, by increasing renal perfusion and reducing intra-abdominal pressure in patients with heart failure and ascites.

The efficacy of both therapeutic strategies in managing volume overload in RCS has been the subject of debate and scientific evidence is limited and often contradictory. Some studies have suggested that ultrafiltration may be more effective than diuretics in reducing body weight, improving kidney function, and decreasing hospitalizations for decompensated heart failure. However, other studies have shown inconsistent results and have not demonstrated a

significant superiority of ultrafiltration over heavy diuretic use.

Importantly, the choice between intensive diuretic use and ultrafiltration should be based on individualized assessment of each patient, taking into account the severity of volume overload, renal function, diuretic tolerance, and other comorbidities. Both therapeutic strategies have their own advantages and disadvantages, and there is no "one size fits all" for managing volume overload in SCR.

Safety and Tolerability

Heavy use of diuretics is associated with certain complications, especially depletion of electrolytes such as potassium and magnesium, which can lead to cardiac arrhythmias and muscle weakness. In addition, resistance to diuretics can develop over time, limiting their long-term effectiveness in managing volume overload.

On the other hand, ultrafiltration can also have its own complications, including those related to vascular access, such as catheter insertion site infections and venous thrombosis. In addition, ultrafiltration may require careful monitoring and adjustment to avoid fluid and electrolyte imbalances and ensure controlled fluid removal.

It is important for healthcare professionals to be vigilant for these complications and closely monitor patients undergoing any therapeutic approach for volume overload in SCR. Informed decision-making and proper monitoring are essential to ensure the safety and tolerability of both approaches.

Economic Considerations and Availability

Intensive use of diuretics is widely available and relatively inexpensive, making it an affordable therapeutic option in different clinical settings. On the other hand, ultrafiltration may require a more specialized infrastructure and trained personnel, which may limit its availability and accessibility in some health institutions.

In addition, ultrafiltration can have a higher associated cost due to the need for specialized equipment and devices, as well as the supervision and personalized attention it requires. These economic and availability considerations should also be taken into account when evaluating the feasibility of ultrafiltration as a therapeutic strategy in the management of SCR.

Need for Comparative Studies

Although there are studies that have compared intensive diuretic use with ultrafiltration in the management of volume overload in CRS, most of these studies are small in size, with methodological limitations and inconsistent results. Well-designed, larger-scale comparative trials are needed to establish the superiority of one strategy over the other and to identify the precise indications and patient populations that would benefit most from each approach.

In addition, attention should be paid to the selection of patients for each therapeutic strategy, considering factors such as severity of volume overload, renal function, tolerance to diuretics and other comorbidities. An individualized, evidence-based approach is essential to optimize clinical outcomes and quality of life for patients with SCR.

CONCLUSIONS

Managing volume overload in cardiorenal syndrome due to overload is a complex challenge for healthcare professionals. Both intensive use of diuretics and ultrafiltration are therapeutic strategies that offer potential benefits and risks. The choice between both approaches should be based on careful assessment of each patient and should consider the severity of volume overload, renal function, diuretic tolerance, and other comorbidities.

In addition, well-designed, larger-scale comparative trials are needed to establish the superiority of one strategy over the other and to identify the precise indications and patient populations that would benefit most from each approach. In-depth knowledge of the clinical and pathophysiological characteristics of RCS, as well as the therapeutic options available, is essential to optimize the care of patients affected by this complex entity.

Ultimately, a multidisciplinary and individualized approach, based on evidence and clinical experience, is essential to improve clinical outcomes and quality of life for patients with SCR and volume overload. Collaboration between cardiologists, nephrologists and other specialists is critical to comprehensively address the complex pathophysiological interactions in CRS and provide optimal, personalized management for each patient.

REFERENCES

I. Chen, H. Y., Chou, K. J., Fang, H. C., Chen, C. L., Hsu, C. Y., Huang, W. C., ... & Lee, P. T. (2015). Effect of ultrafiltration versus intravenous furosemide for decompensated heart failure in cardiorenal syndrome: a systematic review with meta-analysis of randomized controlled trials. Nephron, 129(3), 189-196.

II. Lim, S. Y., & Kim, S. (2021). Pathophysiology of Cardiorenal Syndrome and Use of Diuretics and Ultrafiltration as volume control. Korean Circulation Journal, 51(8), 656-667.

III. Pokhrel, N., Maharjan, N., Dhakal, B., & Arora, R. R. (2008). Cardiorenal syndrome: A literature review. Experimental & Clinical Cardiology, 13(4), 165.

IV. Obi, Y., Kim, T., Kovesdy, C. P., Amin, A. N., & Kalantar-Zadeh, K. (2016). Current and potential therapeutic strategies for hemodynamic cardiorenal syndrome. Cardiorenal medicine, 6(2), 83-98.

V. Ronco, C., Kaushik, M., Valle, R., Aspromonte, N., & Peacock IV, W. F. (2012, January). Diagnosis and management of fluid overload in heart failure and cardio-renal syndrome: the “5B” approach. In Seminars in nephrology (Vol. 32, No. 1, pp. 129-141). WB Saunders.

VI. Ross, E. A., & Kazory, A. (2012). Ultrafiltration therapy for cardiorenal syndrome: physiologic basis and contemporary options. Blood purification, 34(2), 149-157.

VII. Liang, K. V., Williams, A. W., Greene, E. L., & Redfield, M. M. (2008). Acute decompensated heart failure and the cardiorenal syndrome. Critical care medicine, 36(1), S75-S88.

VIII. Reis, T., Ronco, F., & Ostermann, M. (2023). Diuretics and ultrafiltration in heart failure. Cardiorenal Medicine, 13(1), 56-65.

IX. Kazory, A., & Costanzo, M. R. (2018). Extracorporeal isolated ultrafiltration for management of congestion in heart failure and cardiorenal syndrome. Advances in Chronic Kidney Disease, 25(5), 434-442.

X. Kwong, J. S., & Yu, C. M. (2014). Ultrafiltration for acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trials. International journal of cardiology, 172(2), 395-402.